Last update 15 Oct 2025

HLN601

Overview

Basic Info

Drug Type
Small molecule drug, Liposomal Drug
Synonyms
注射用HLN601脂质体
Target-
Action-
Mechanism-
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [1]
Active Indication
Advanced Malignant Solid NeoplasmBreast CancerColorectal Cancer+ [1]
Inactive Indication-
Originator Organization
Hongliang (Shanghai) Biomedical Technology Co., Ltd.
Active Organization
Hongliang (Shanghai) Biomedical Technology Co., Ltd.Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of SciBohai Rim Advanced Research Institute for Drug Discovery
+ [1]
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with HLN601
CTR20244716
/ RecruitingPhase 1
评价注射用 HLN601 脂质体在晚期实体瘤患者中的安全性、耐受性及药代动力学特征和初步疗效的多中心、开放的 I 期临床试验
[Translation] A multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of HLN601 liposome for injection in patients with advanced solid tumors
100 Clinical Results associated with HLN601
Login to view more data
100 Translational Medicine associated with HLN601
Login to view more data
100 Patents (Medical) associated with HLN601
Login to view more data
100 Deals associated with HLN601
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 1
China
Bohai Rim Advanced Research Institute for Drug Discovery
07 Feb 2025
Advanced Malignant Solid NeoplasmPhase 1
China
Yantai Institute of Materia MedicaYantai Institute of Materia Medica
07 Feb 2025
Advanced Malignant Solid NeoplasmPhase 1
China
Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
07 Feb 2025
Advanced Malignant Solid NeoplasmPhase 1
China
Hongliang (Shanghai) Biomedical Technology Co., Ltd.
07 Feb 2025
Breast CancerIND Approval
China
Hongliang (Shanghai) Biomedical Technology Co., Ltd.
26 Feb 2024
Breast CancerIND Approval
China
Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
26 Feb 2024
Breast CancerIND Approval
China
Bohai Rim Advanced Research Institute for Drug Discovery
26 Feb 2024
Colorectal CancerIND Approval
China
Hongliang (Shanghai) Biomedical Technology Co., Ltd.
26 Feb 2024
Colorectal CancerIND Approval
China
Bohai Rim Advanced Research Institute for Drug Discovery
26 Feb 2024
Colorectal CancerIND Approval
China
Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
26 Feb 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free